Diagnosis and dynamic control of vascular disorders in patients with amiodarone-induced pulmonary toxicity (AIPT)

Introduction. In the structure of interstitial lung diseases, drug­induced lung lesions occur in approximately 3 % of cases. One of the most pneumotoxic drugs used in cardiology is amiodarone. Its toxic effect is multicomponent and affects all structures of the bronchopulmonary system.

Objective of the study was to estimate radiologic features and to follow up vascular disorders in the lungs in patients with amiodarone­induced pulmonary toxicity (AILT)

Material and methods. We included 214 CT exams of 110 patients with history of amiodaron use. AILT was confrmed in 90 cases. In 81 % of patients we repeated CT exams 2–5 times, with observation period from 1 month up to 10 years. The mean age of patients was 71 years (21 females, 69 – males). In 52 % of patients lung scintigraphy was performed, in 34 % with follow up (from 2 to 4 times). We included functional lung test and cardiac ultrasound in diagnostic plan.

Results. Three clinical and radiological forms of the disease were identifed: acute, subacute, and chronic. The acute form was observed in 3 % of cases, the subacute (in 68 %), the chronic form was determined during the frst examination (23 %) and during the transformation from the subacute form (38 %). According to SPECT­CT data 70 % of patients had pronounced diffuse microcirculation disorders, 30 % of patients developed perfusion disorders of moderate severity.

Conclusion. There are persistent and irreversible changes in the lungs with AIPT in dynamic radiological examination, there is a tendency to fbrosis and recurrence and perfusion disorders in the lungs during treatment are not fully recovered. For suspected pulmonary embolism most informative diagnostic method is SPECT.

1. Ilkovich MM. Interstitial and orthopedic lung diseases. Library specialist doctor. Geotar. 2016;560. (In Russ.).

2. Ward DE, Camm AJ & Spurrell RA. Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tadiсardias. J. Br Heart J. 1980;44:91–95. Doi: 10.1136/hrt.44.1.91.

3. Berghaus T, Haeckel T. et al. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Schwaiblmair Clin Res Cardiol. 2010;99:693–700. Doi: /10.1007/s00392-010-0181-3.

4. Raymond E Dusmanт, Marshall S Stanton, William M Miles, Lawrence S. Klein, Douglas P Zipes, Naomi S Fineberg, and James J Heger. Clinical Features of AmiodaroneInduced Pulmonary Toxicity. Circulation. 1990;82:51–59. Doi:10.1161/01.cir.82.1.51.

5. Van Mieghem W, Coolen L, Malysse I et al. Amiodarone and the development of ARDS after lung surgery. Chest. 1994;105:1642–1645. Doi: 10.1378/chest.105.6.1642.

6. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Singh Arch Intern Med. 2000;160(12):1741. Doi: 10.1001/archinte.160.12.1741.

7. Lyle A, Siddoway MD. Amiodarone: Guidelines for Use and Monitoring. Am Fam Physician 2003;68:2189–2196. Doi: 10.1016/0002-8703(83)90021-2.

8. Jessurun GA, Crijns HJ. Amiodarone pulmonary toxicity. Physicians’ desk reference. 56th ed. Montvale, N. J. Medical Economics, BMJ. 1997;314:1831. Doi:10.1136/bmj.314.7081.619.

9. Desak Ketut Ernawati, Leanne Stafford and Jeffery David Hughes. Br. Amiodarone-induced pulmonary toxicity. J Clin Pharmacol. 2008;66(1):82–87. Doi: 10.1111/j.1365-2125.2008.03177.x.

10. Akoun GM, Cadrane JL, Blanchette G, Milleron BJ, Mayaud CM., Blanchette G, Milleron BJ, Mayaud CM. Bronchoalveolar lavage cell data in amiodarone-associated pneumonitis. Evaluation in 22 patients. Chest. 1991;99(5):1177– 1182. Doi: 10.1378/chest.99.5.1177.

11. Mankikian J, Favelle O, Guillon A, Guilleminault L, Cormier B. Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respiratory Medicine. 2014;108(4):638–646. Doi: 10.1016/j.rmed.2014.01.014.

12. Kennedy JI, Myers JL, Plumb VJ, Fulmer JD. Amiodarone Pulmonary Toxicity: Clinical, Radiologic, and Pathologic Correlations. Archives of Internal Medicinе. 1987;147(1):50– 55. Doi: 10.1001/archinte.147.1.50.

13. Vasić RN et al. Drug induced lung disease – amiodarone in focus. Drug induced lung disease – 334. Doi: 10.2298/mpns1410334v.

14. Kreider ME, Hansen-Flaschen J, Ahmad NN et al. Complication of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann. Thorac. Surg. 2007;83:1140–1144. Doi: 10.1016/j.athoracsur.2006.10.002.

15. Elikowski W, Cofta S, Nowicski A et al. Recurrent hemoptysis following thienopyridines and amidarone administration. Therpeutic dilemma. Pol. Arch. Med. Wewn. 2005;114(2):773–778.

16. Makinodan K, Itoh T, Tomoda K, Tamaki S, Koyama N, Yoshikawa M, Hamada K, Kimura H. Acute pulmonary thromboembolism associated with interstitial pneumonia. Intern Med. 2008;47:647–650. Doi: 10.2169/internalmedicine.47.0588.

17. McLaughlin V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology. 2009;48:25–31. Doi: 10.1093/rheumatology/kep107.

18. Updated Clinical Classifcation of Pulmonary Hypertension from 4th World symposium (Dana Point, 2008). Doi: 10.1093/med/9780199572564.003.003.

19. A Mechanistic Study on the Amiodarone-Induced Pulmonary Toxicity. Hindawi Publishing Corporation Oxidative Medicine and Cellular Longevity. 2016;6265853:10. Doi: 10.1155/2016/6265853.

20. Vereckei A, Blazovics A, Gyorgy I et al. The role of free radicals in the pathogenesis of amiodarone toxicity. Journal of Cardiovascular Electrophysiology. 1993;4(2):161–177. Doi: 10.1111/j.1540-8167.1993.tb01220.x.

21. Nicolescu AC, Сomeau JL, Hill BC et al. Aryl radical involvement in amiodarone-induced pulmonary toxicity: investigation of protection by spin-trappingnitrones. Тoxicology and Applied Pharmacology. 2007;220(1):60–71. Doi: 10.1016/j.taap.2006.12.031.

22. Chung WH, Bennett BM, Racz WJ, Brien JF, Massey TE. Induction of c-jun and TGF-β1 in Fischer 344 rats during amiodarone-induced pulmonary fbrosis. American Journal of Physiology–Lung Cellular and Molecular Physiology, 2001;281(5):1180–1188. Doi: 10.1152/ajplung.2001.281.5.l1180.

23. Mahavadi P, Knudsen L, Venkatesan S, Henneke I. Regulation of macroautophagy in amiodarone-induced pulmonary fbrosis. J Pathol. Clin Res. 2015:1(4):252–263. Doi: 10.1002/cjp2.20.

24. Kachel DL, Moyer TP, Martin WJ. Amiodarone-induced injury of human pulmonary artery endothelial cells: protection by alpha-tocopherol. Journal of Pharmacology and Experimental Therapeutics. 1990;254(3):1107–1112. Doi: 10.1016/0041-008x(90)90271-u.